Spots Global Cancer Trial Database for GW572016 For Treatment Of Refractory Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GW572016 For Treatment Of Refractory Metastatic Breast Cancer
Official Title: An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
Study ID: NCT00062686
Conditions
Interventions
Study Description
Brief Summary: This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
GSK Investigational Site, Buenos Aires, , Argentina
GSK Investigational Site, Villejuif Cedex, , France
GSK Investigational Site, Augsburg, Bayern, Germany
GSK Investigational Site, Sutton, Surrey, United Kingdom
GSK Investigational Site, Bebington, Wirral, , United Kingdom
GSK Investigational Site, London, , United Kingdom
GSK Investigational Site, Manchester, , United Kingdom
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
